| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/23/2010 | US20100239607 Compositions for inducing immune responses |
| 09/23/2010 | US20100239587 Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors; for preventing, treating, and diagnosing mammalian cancer tumors |
| 09/23/2010 | US20100239563 Pharmaceutical composition for the prophylaxis and/or treatment of viral diseases |
| 09/23/2010 | US20100239530 Ifnar2 mutants, their production and use |
| 09/23/2010 | CA2755697A1 Amide derivative |
| 09/23/2010 | CA2755209A1 Compound for the treatment of tuberculosis |
| 09/23/2010 | CA2753897A1 Methods for modulating metabolic and circadian rhythms |
| 09/22/2010 | EP2230320A1 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| 09/22/2010 | EP2230307A1 Neutrokine alpha |
| 09/22/2010 | EP2230254A2 Anti-IGFR1 antibody therapeutic combinations |
| 09/22/2010 | EP2229943A1 Compounds for use in the treatment of peripheral neuropathy |
| 09/22/2010 | EP2229940A1 Pharmaceutical composition presenting anti-inflammatory and anti-histaminic properties |
| 09/22/2010 | EP2229185A2 Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| 09/22/2010 | EP2229164A1 Elevation of the plasma hdl-cholesterol level |
| 09/22/2010 | EP1962094B1 Detecting agent and therapeutic agent for highly malignant breast cancer |
| 09/22/2010 | EP1809271B9 Use of (r)-(halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators |
| 09/22/2010 | EP1401853B1 Modulators of pharmacological agents |
| 09/22/2010 | CN1612746B Use of HEPCIDIN as a regulator of iron homeostasis |
| 09/22/2010 | CN101842103A Unit dosage for brain health |
| 09/22/2010 | CN101837129A Medicament composition containing cMet inhibitor, HDAC (Histone Deacetylases) inhibitor and EGFR (Epidermal Growth Factor Receptor) tyrosine kinase inhibitor and application thereof |
| 09/22/2010 | CN101837128A Medicament composition containing sorafenib, MEK inhibitors and EGFR tyrosine kinase inhibitors and application thereof |
| 09/22/2010 | CN101837127A Medical use of inhibitors of glutaminyl and glutamate cyclases |
| 09/22/2010 | CN101837126A Cephalosporin antibacterial combination and medicinal preparation thereof |
| 09/22/2010 | CN101836964A Antibiotic and use method of control agent for controlling micro organism quantity |
| 09/22/2010 | CN101836963A Medicinal application preparation for curing hypertension |
| 09/22/2010 | CN101836949A Transcutaneous gel preparation containing antiemetic active medicaments and preparation method thereof |
| 09/21/2010 | US7799901 capable of modulating or mediating the FAS receptor ligand or TNF effect on cells carrying FAS receptor or p55 receptor by binding or interacting with MORT-1 (mediators of receptor toxicity) protein |
| 09/21/2010 | US7799897 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
| 09/21/2010 | US7799833 System and method for the pretreatment of the endplates of an intervertebral disc |
| 09/21/2010 | US7799832 Especially tolperisone or its analogs eperisone or silperisone, or riluzole, propafenone, lidocaine, flecainide or metixen or their salts; treating pains which are accompanied by an increase in muscle tone |
| 09/21/2010 | US7799794 Treatment for cardiovascular disease |
| 09/21/2010 | US7799775 Pyrimidine derivatives |
| 09/21/2010 | US7799771 solid dosage form for contraceptives and hormone replacement therapy; very low moisture content to prevent ester hydrolysis; enhanced bioavailability of 17-beta-estradiol acetate; FDA Orange book listed patent for estradiol acetate |
| 09/21/2010 | US7799766 Composition for treating hormonally-dependent cancers |
| 09/21/2010 | US7799763 Muscle-strengthening drugs and anti-inflammatory drugs |
| 09/21/2010 | US7799541 for Systemic Inflammatory Response Syndrome (SIRS), including severe sepsis, septic shock and sepsis related to cardiac dysfunction |
| 09/21/2010 | US7799351 Metal compounds, mixed or sulphated, as phosphate binders |
| 09/21/2010 | US7799337 Method for directed intranasal administration of a composition |
| 09/21/2010 | US7799335 Differential delivery of nitric oxide |
| 09/21/2010 | US7799329 Viruses for the treatment of cellular proliferative disorders |
| 09/21/2010 | US7799324 Using undifferentiated embryonic stem cells to control the immune system |
| 09/21/2010 | CA2481229C Substituted pyrazine inhibitors of akt |
| 09/21/2010 | CA2458415C 24-sulfur-substituted analogs of 1.alpha.,25-dihydroxy vitamin d3 |
| 09/21/2010 | CA2429308C Novel lactam-substituted pyrazolopyridine derivatives |
| 09/21/2010 | CA2416650C Enhancement of the action of central and peripheral nervous system agents |
| 09/21/2010 | CA2408746C Antisense phosporodiamidate morpholino oligonucleotide inhibition of cytochrome p450 to modulate drug pharmacokinetics |
| 09/21/2010 | CA2387539C Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
| 09/21/2010 | CA2376916C Anaesthetic formulation comprising an nmda-antagonist and an alpha-2 adrenergic agonist |
| 09/21/2010 | CA2345659C Biodegradable low molecular weight triblock polyester polyethylene glycol copolymers having reverse thermal gelation properties |
| 09/21/2010 | CA2299950C Oral adhesive sheet and oral adhesive preparation |
| 09/21/2010 | CA2225788C Therapeutic agents and autoimmune diseases |
| 09/16/2010 | WO2010105016A1 Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment |
| 09/16/2010 | WO2010104176A1 Mega-phosphoprotein cleavage inhibitor |
| 09/16/2010 | WO2010103851A1 Method for determining sensitivity to irinotecan and use thereof |
| 09/16/2010 | WO2010103845A1 External preparation containing analgesic/anti-inflammatory agent |
| 09/16/2010 | WO2010103844A1 External preparation containing analgesic/anti-inflammatory agent |
| 09/16/2010 | WO2010103843A1 External preparation containing analgesic/anti-inflammatory agent |
| 09/16/2010 | US20100234461 Compositions For Improved Oxidative Status In Companion |
| 09/16/2010 | US20100234430 Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments |
| 09/16/2010 | US20100234382 Composition comprising a pde4 inhibitor and a pde5 inhibitor |
| 09/16/2010 | US20100234368 Condensed ring compound and use thereof |
| 09/16/2010 | US20100234353 Sulfonylamino-derivatives as novel inhibitors of histone deacetylase |
| 09/16/2010 | US20100234337 Foaming compositions for hair care |
| 09/16/2010 | US20100234332 Novel quinuclidine derivatives and medicinal compositions containing the same |
| 09/16/2010 | US20100233785 Novel methods and interferon deficient substrates for the propagation of viruses |
| 09/16/2010 | US20100233735 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 09/16/2010 | US20100233722 Methods for determining the biological effect and/or activity of r pharmaceutical compositions based on their effect on the methylation status of the DNA |
| 09/16/2010 | US20100233297 Systemic administration of nac as an adjunct in the treatment of terrorism exposures such as radiation and for prophylaxis |
| 09/16/2010 | US20100233264 TEMPERATURE AND pH-SENSITIVE BLOCK COPOLYMER HAVING EXCELLENT SAFTY IN VIVO AND HYDROGEL AND DRUG DELIVERY SYSTEM USING THEREOF |
| 09/16/2010 | US20100233254 Multi-phase, multi-compartment, capsular delivery apparatus and methods for using the same |
| 09/16/2010 | US20100233193 Systemic administration of nac for vaccination prophylaxis |
| 09/16/2010 | US20100233169 Methods for treating obesity using fibroblast growth factor-Like polypeptides |
| 09/16/2010 | US20100233166 Novel ido inhibitors and methods of use |
| 09/16/2010 | US20100233158 Induction of immune tolerance |
| 09/16/2010 | DE112008002647T5 Antidiarrhöische Zusammensetzung, Produkte, die diese enthalten, und Verfahren zum Schutz vor Diarrhö Antidiarrheal composition, products containing them, and methods for protection against diarrhea |
| 09/16/2010 | CA2754909A1 Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment |
| 09/15/2010 | EP2228654A2 Diagnosis and prevention of cancer cell invasion |
| 09/15/2010 | EP2228389A2 Antibodies against vascular endothelial growth factor 2 |
| 09/15/2010 | EP2228035A1 Use of alginate matrices to control cell growth |
| 09/15/2010 | EP2227213A1 Compositions and methods for treating vaginal infections and pathogenic vaginal biofilms |
| 09/15/2010 | EP1631294B1 A method of treating an anxiety disorder |
| 09/15/2010 | EP1536839B1 Combination therapy comprising omega-interferon for treating infection with hepatitis c virus or yellow fever virus |
| 09/15/2010 | EP1501819B1 Estrogen receptor modulators |
| 09/15/2010 | EP1430140B1 N-terminally truncated isoforms of pde3a cyclic phosphodiesterases |
| 09/15/2010 | EP1354196B1 Diagnostics, drug screening and treatment for cancer |
| 09/15/2010 | EP1351681B1 Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts |
| 09/15/2010 | EP1303596B1 Morpholino antisense oligomers as enzyme inhibitors for improving pharmacokinetics of a drug |
| 09/15/2010 | CN201578612U Combined capsule filled with angiotonin II acceptor antagonist solid preparation and hydrochlorothiazidum solid preparation |
| 09/15/2010 | CN101835491A Agent for promoting corneal endothelial cell adhesion |
| 09/15/2010 | CN101830889A 嘧啶衍生物 Pyrimidine derivatives |
| 09/15/2010 | CN101829329A Tooth antiallergic composition |
| 09/15/2010 | CN101829328A Drug for treating amphetamine-type exhilarant dependence syndrome and amphetamine-type exhilarant and opioid mixed dependence syndrome |
| 09/15/2010 | CN101829327A Drug combinations of chloroquine and protease inhibitors, and application thereof |
| 09/15/2010 | CN101829120A Composition for treatment of external secretion disorders |
| 09/15/2010 | CN101829114A Application of ilaprazole for preparing reflux esophagitis drug |
| 09/15/2010 | CN101829061A Taxol nanoparticle composition and preparation method thereof |
| 09/15/2010 | CN101283933B Artificial crystalline lens of blocking eaves type limitation after cataract |
| 09/15/2010 | CN101254308B Biogastrone acid-polyethyleneglycol /chitosan liver target composite drug administration system and preparation thereof |
| 09/15/2010 | CN101229373B Medicine compounds for treating diabetic nephropathy |
| 09/15/2010 | CN101069660B Preparing method of biliary-tract carriage carrying about medicine |